aridis is a privately held infectious diseases focused company in san jose, ca, usa. aridis’ advanced formulation and delivery technologies are combined with proprietary products portfolio to create potent drug candidates that are packaged into convenient to administer, "ready-to-use" formats.
Company profile
Ticker
ARDS
Exchange
Website
CEO
Vu L. Truong
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aridis Biopharmaceuticals LLC • Aridis Pharmaceuticals C.V. ...
IRS number
320074500
ARDS stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
16 Jan 24
DEFA14A
Additional proxy soliciting materials
18 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Dec 23
DEFA14A
Additional proxy soliciting materials
15 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results
3 Nov 23
DEFA14A
Additional proxy soliciting materials
3 Nov 23
ARS
2022 FY
Annual report to shareholders
2 Nov 23
DEF 14A
Definitive proxy
2 Nov 23
10-Q
2023 Q2
Quarterly report
13 Sep 23
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
JOHN F HAMILTON
19 Sep 23
4
Susan Richards Windham-Bannister
19 Sep 23
4
Eric Patzer
19 Sep 23
4
Vu Truong
19 Sep 23
4
Hasan Jafri
19 Sep 23
4
Eric Patzer
15 Jun 23
4
JOHN F HAMILTON
15 Jun 23
4
Vu Truong
15 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 535.00 k | 535.00 k | 535.00 k | 535.00 k | 535.00 k | 535.00 k |
Cash burn (monthly) | (no burn) | 216.50 k | 289.67 k | 73.58 k | 327.67 k | 1.49 mm |
Cash used (since last report) | n/a | 1.29 mm | 1.73 mm | 439.80 k | 1.96 mm | 8.91 mm |
Cash remaining | n/a | -759.00 k | -1.20 mm | 95.20 k | -1.42 mm | -8.37 mm |
Runway (months of cash) | n/a | -3.5 | -4.1 | 1.3 | -4.3 | -5.6 |
Institutional ownership, Q2 2023
23.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 22 |
Opened positions | 3 |
Closed positions | 6 |
Increased positions | 4 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 240.35 mm |
Total shares | 11.03 mm |
Total puts | 0.00 |
Total calls | 19.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cystic Fibrosis Foundation | 5.17 mm | $5.12 mm |
Lind Global Fund II | 3.00 mm | $1.13 mm |
AZN Astrazeneca | 884.96 k | $0.00 |
Commonwealth Equity Services | 646.00 k | $142.00 k |
Roumell Asset Management | 446.59 k | $98.21 mm |
STT State Street | 202.25 k | $44.47 mm |
Geode Capital Management | 143.03 k | $31.45 mm |
Francis Capital Management | 142.84 k | $0.00 |
Vanguard | 136.20 k | $29.95 mm |
HRT Financial | 73.72 k | $16.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Sep 23 | John F Hamilton | Stock Options Common Stock | Grant | Acquire A | No | No | 0.08 | 15,000 | 1.20 k | 91,540 |
18 Sep 23 | Susan Richards Windham-Bannister | Stock Options Common Stock | Grant | Acquire A | No | No | 0.08 | 15,000 | 1.20 k | 73,500 |
18 Sep 23 | Eric Patzer | Stock Options Common Stock | Grant | Acquire A | No | No | 0.08 | 15,000 | 1.20 k | 161,862 |
18 Sep 23 | Vu Truong | Stock Options Common Stock | Grant | Acquire A | No | No | 0.08 | 30,000 | 2.40 k | 817,750 |
18 Sep 23 | Hasan Jafri | Stock Options Common Stock | Grant | Acquire A | No | No | 0.08 | 20,000 | 1.60 k | 175,000 |